4D Molecular Therapeutics (FDMT) Operating Income (2020 - 2025)
Historic Operating Income for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Q3 2025 value amounting to -$61.2 million.
- 4D Molecular Therapeutics' Operating Income fell 1966.09% to -$61.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$230.4 million, marking a year-over-year decrease of 3682.41%. This contributed to the annual value of -$187.8 million for FY2024, which is 6642.69% down from last year.
- Per 4D Molecular Therapeutics' latest filing, its Operating Income stood at -$61.2 million for Q3 2025, which was down 1966.09% from -$59.5 million recorded in Q2 2025.
- In the past 5 years, 4D Molecular Therapeutics' Operating Income ranged from a high of -$7.6 million in Q2 2021 and a low of -$61.2 million during Q3 2025
- Over the past 5 years, 4D Molecular Therapeutics' median Operating Income value was -$30.1 million (recorded in 2023), while the average stood at -$34.5 million.
- Its Operating Income has fluctuated over the past 5 years, first skyrocketed by 4985.81% in 2021, then crashed by 27422.33% in 2022.
- Over the past 5 years, 4D Molecular Therapeutics' Operating Income (Quarter) stood at -$24.8 million in 2021, then decreased by 15.97% to -$28.7 million in 2022, then decreased by 27.62% to -$36.7 million in 2023, then crashed by 53.11% to -$56.1 million in 2024, then dropped by 9.03% to -$61.2 million in 2025.
- Its Operating Income stands at -$61.2 million for Q3 2025, versus -$59.5 million for Q2 2025 and -$53.6 million for Q1 2025.